04:31 AM EST, 12/10/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) said late Tuesday it has priced its public offering of 7 million common shares at $86 per share for gross proceeds of $602 million.

Underwriters have been granted a 30-day option to purchase up to an additional 1.1 million shares.

Kymera said it intends to use proceeds to advance its pipeline of preclinical and clinical degrader programs, and for working capital and other general corporate purposes.

The offering is expected to close on Thursday, the company said.